Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Asmakast vs Singulair in Healthy Adults
NCT02479854Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Apr 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of montelukast in asthma and allergic rhinitis (AR) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration at 24 hours, Area under the plasma concentration-time curve from time zero to the last measurable concentration at 24 hours and 1 more. Started Apr 2014; status: completed.
02
Drugs
montelukast
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02479854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02479854.